MiMedx Group (NASDAQ:MDXG) Hits New 12-Month Low – Time to Sell?

Shares of MiMedx Group, Inc (NASDAQ:MDXG) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $4.70 and last traded at $4.82, with a volume of 676785 shares traded. The stock had previously closed at $4.76.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MDXG. Cantor Fitzgerald reduced their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Citizens Jmp began coverage on MiMedx Group in a research report on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 price objective for the company. Wall Street Zen downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Finally, Lake Street Capital lowered their price target on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.60.

MiMedx Group Price Performance

The firm has a market cap of $668.57 million, a PE ratio of 14.06 and a beta of 1.60. The company has a current ratio of 4.32, a quick ratio of 3.92 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average price of $5.47 and a 200 day moving average price of $6.49.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to the consensus estimate of $106.78 million. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%. On average, sell-side analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MDXG. Royal Bank of Canada boosted its position in shares of MiMedx Group by 1.4% in the 1st quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock worth $7,466,000 after buying an additional 13,629 shares in the last quarter. AQR Capital Management LLC increased its holdings in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after acquiring an additional 4,296 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in MiMedx Group during the first quarter worth about $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in MiMedx Group by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after acquiring an additional 4,049 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of MiMedx Group by 93.9% in the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock valued at $9,355,000 after purchasing an additional 596,016 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.